Healthcare Sector Expertise
National has developed a unique area of expertise in the healthcare sector, drawing upon the deep knowledge base of our bankers, analysts and advisors as well as practitioners in major research and medical centers around the country. National’s healthcare banking team has a track record of successful financings of R&D and clinical stage biotech and medical device companies targeting unmet medical needs in significant markets including cancer, pain management, diabetes, cardiovascular, autoimmune, neurological, and digestive conditions.
Our retail and institutional investors benefit from our team’s ability to identify and finance private and public life sciences and medical technology companies through a wide range of transaction structures including straight equity, convertibles, and notes in Stage A raises, pre-listing bridge financings, IPOs, Follow-Ons, CMPOs, and RDOs.
Healthcare Sector Coverage
National broadly covers the healthcare sector but maintains a particular focus on micro and small cap companies developing drugs to treat cancer, microbial infection, and pain. We also maintain dedicated coverage of several medical device companies.
Healthcare spending currently accounts for almost 20% of US GDP, higher than any other nation by a wide margin. The healthcare sector is expected to continue to thrive given increasing pressure on the FDA to accelerate its pace of drug application review, the JOBS Act, as well as ongoing political efforts to reduce the cost of healthcare. These dynamics have encouraged ever-higher numbers of micro and small cap healthcare companies.
We believe that through our due diligence and increasing number of healthcare investment opportunities, investors can continue to find attractive investment option in the sector.
Aerpio Pharmaceuticals, Inc. (ARPO: Buy, $15 TP)
November 7, 2018– This morning, Aerpio announced 3Q18 financial results and provided clinical and operational updates, reporting a cash position of $68.8M, enough to fund the company comfortably through 1Q20 per our projections, almost a year after the expected data readout of the TIME-2b trial for AKB-9778.
Akebia Therapeutics, Inc. (AKBA: Buy, $18 PT)
November 9, 2018–Yesterday, Akebia reported 3Q18 financial results and provided an update on operational and clinical developments. Akebia reported cash of $390M at quarter’s end, enough to fund operations into 2020, per our projections.
Assembly Biosciences, Inc. (ASMB: Buy, $70 PT)
November 8, 2018– Assembly released 3Q18 financial results and provided clinical and operational updates, reporting a cash position of$233.9M, which includes $155M raised through a public offering in July.
Avenue Therapeutics, Inc. (ATXI: Buy, $14 PT)
November 15, 2018– Avenue reported 3Q18 results and provided clinical and operational updates. The company reported $4.8M in cash, which when combined with the expected $35M from InvaGen in 1Q19 and the additional $7M potential line of credit, is sufficient to fund the company into early 2021, in our estimate which importantly is when the company should have fulfilled the requirements for its full acquisition.
AVEO Pharmaceuticals, Inc. (AVEO: Neutral)
November 6, 2018– Yesterday after market, Aveo announced topline results from the TIVO-3 trial to compare tivozanib with sorafenib in advanced or metastatic renal cell carcinoma (RCC). The trial met its primary endpoint, with a statistically significant improvement in progression-free survival compared with sorafenib. No mature data were available for the secondary endpoint of overall survival (OS), but thus far OS is trending against Aveo; the full OS analysis is planned for August, 2019. Based on the results of the trial, Aveo plans to submit a NDA to the FDA in approximately 6 months, but we are concerned that the unfavorable OS trend will continue and hinder FDA approval.
Checkpoint Therapeutics (CKPT: Buy, $18 PT)
November 2, 2018– Checkpoint reported 3Q18 financial results and provided clinical and operational updates, reporting a cash position of$29.6M at the end of the quarter, which should comfortably fund the company into late 2019, as per our projections.
Exellxis, Inc. (EXEL: Buy, $34 PT)
November 2, 2018 — Exelixis reported strong 3Q18 results, with total revenue of $225.4M and diluted EPS of $0.41, both of which beat consensus of $172M and $0.19. Net product revenues were $162.9M and are due to continued growth in sales of Cabometyx (cabozantinib) for advanced renal cell carcinoma (aRCC).
Eyenovia, Inc. (EYEN: Buy, $12 PT)
January 9, 2019 — We are initiating coverage of Eyenovia, Inc. with a Buy rating and a 1-year target price of $12, which is supported by a DCF analysis using a 20% discount rate and a 4 multiple of the terminal value for the projected 2030 EBITDA of $229 million. We base our valuation on revenue from MicroPine in progressive myopia, MicroProst in chronic angle closure glaucoma (CACG), MicroStat for mydriasis, and MicroTears for dry eye, with any commercial success from Eyenovia’s other programs serving
as potential upside to our valuation.
Heron Therapeutics, Inc. (HRTX: Buy, $42 PT)
January 8, 2019– Yesterday, Heron pre-announced 4Q18 revenue of $28.1M ($23M from Cinvanti and $5.1M from Sustol), a 42% increase over 3Q18 for its chemo-induced nausea and vomiting (CINV) drug franchise, and guided 2019 revenue from its CINV franchise to be in the $115 – 120M range, a 53% increase over full year 2018 CINV franchise revenue of $76.7M.
Innovate Biopharmaceuticals, Inc. (INNT: Buy, $27 PT)
November 14, 2018– Yesterday, Innovate released 3Q18 financial results and provided clinical and operational updates, reporting a cash position of $8.1M. Given that Innovate plans to fund its Phase 3 trials of larazotide for celiac disease by securing non-dilutive funds from licensing larazotide in non-strategic countries, the current cash plus the anticipated non-dilutive funding should be sufficient to fund the company until the trials conclude. In the absence of receiving non-dilutive funding, Innovate could do a bona fide capital raise or utilize its ATM facility.
Mustang Bio, Inc. (MBIO: Buy, $21 PT)
November 14, 2018– Mustang reported 3Q18 results and discussed clinical and operational developments, reporting a cash position of $41.3M, enough to fund company operations through 2019, as per our projections.
Progenics Pharmaceuticals, Inc. (PGNX: Buy, $11 PT)
November 8, 2018– This morning, Progenics reported 3Q18 financial results. Progenics’ partner, Bausch Health Companies, reported net Relistor sales of $34.5M, which translated to $5.3M in 3Q18 royalty revenue. Progenics reported a cash position of$148.9M, including $70M from a public offering in August and an additional $4.8M from ATM transactions.
ProQR Therapeutics, Inc. (PRQR: Buy, $23 PT)
November 7, 2018– This morning, ProQR announced 2Q18 results and provided clinical and operational updates, reporting a cash position of €113.7M, enough to fund operations through the end of 2020, as per our projections.
Scynexis, Inc. (SCYX: Buy, $6 PT)
November 13, 2018– SCYNEXIS announced 3Q18 financial results and provided an update on operational and clinical developments, reporting a cash position of $49.5M, enough to fund operations into 2020, as per our projections.
Stemline Therapeutics, Inc. (STML: Buy, $31 PT)
December 7, 2018– At the recent ASH conference, Stemline presented longer term pivotal Elzonris data, demonstrating that median overall survival (OS) has not yet been reached in the 29 first-line patients treated with 12 ug/kg/day Elzonris. Median follow up is now 23 (range of 0.2 – 41) months in a patient population that would otherwise have a median OS of about 1 year. Safety results were also updated, with no additional treatment related adverse events (TRAEs) despite longer treatment duration.
Urogen Pharma LTD (URGN: Buy, $70 PT)
January 8, 2019– This morning, UroGen released positive topline Phase 3 results from the OLYMPUS trial, demonstrating that UGN-101 (mitomycin gel) resulted in a 57% (35/61) complete response (CR) rate among the 61 evaluable patients at 4-6 weeks after treatment. Furthermore, all patients who achieved a CR, who were also evaluated at 6 months, remain disease free at 6 months; UroGen currently has 6-month durability data on half of these 35 patients. We anticipate at least some further details when management presents on January 10, such as treatment durability details..